Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

Introduction Cardiac Emergencies

Introduction Cardiac Emergencies

Cardiac emergencies are critical situations involving the heart that require immediate medical intervention to prevent severe complications or death. These emergencies often arise from underlying heart conditions that impair the heart's ability to function correctly.Types of Cardiac EmergenciesThe most common types of cardiac emergencies include Acute Coronary Syndrome (ACS), myocardial infarction (MI), cardiac arrest, and heart failure.Acute Coronary Syndrome (ACS)Acute Coronary Syndrome (ACS)...

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

An 85-Year-Old Woman with Unexplained Hypoxia.

Annals of the American Thoracic Society·2024

Same author

A prospective intravascular ultrasound investigation of the necessity for and efficacy of postdilation beyond nominal diameter of 3 current generation DES platforms for the percutaneous treatment of the left main coronary artery.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2013

Same author

An audit of outcomes after same-day discharge post-PCI in acute coronary syndrome and elective patients.

Journal of interventional cardiology·2013

Same author

Differentiating Alzheimers dementia from dementia with Lewy bodies remains challenging.

Biomarkers in medicine·2011

Same author

Worldwide variation in temporal trends of serum cholesterol levels: a target for future health policy.

Biomarkers in medicine·2011

Same author

CKMB and troponin I levels post coronary artery bypass surgery show a graded association with mortality.

Biomarkers in medicine·2011

Search research articles

Related Experiment Video

Updated: Jun 17, 2026

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

Recent advances in cardiology.

Ian A Menown¹, James A Shand

¹Craigavon Cardiac Centre, Southern Trust, Northern Ireland, BT63 5QQ, UK. ian.menown@southerntrust.hscni.net

Future Cardiology

|December 18, 2009

Summary

This summary is machine-generated.

Cardiology trials in 2009 introduced new findings in anticoagulation, antiplatelet therapy, and percutaneous coronary interventions. These advancements impact the management of coronary disease and heart failure.

More Related Videos

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

Published on: August 2, 2024

Related Experiment Videos

Last Updated: Jun 17, 2026

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

Published on: August 2, 2024

Area of Science:

Cardiology
Clinical Trials
Pharmacology

Background:

2009 saw significant advancements in cardiovascular medicine.
Numerous major clinical trials were published, impacting treatment guidelines.

Purpose of the Study:

To summarize and contextualize key findings from 2009 cardiology trials.
To provide clinical insights into new therapeutic strategies.

Main Methods:

Review and synthesis of major cardiology trial data presented or published in 2009.
Categorization of findings by therapeutic area: anticoagulation, antiplatelet therapy, percutaneous coronary management, medical therapy, and heart failure management.

Main Results:

New anticoagulants like dabigatran showed promise.
Novel antiplatelet agents (ticagrelor, prasugrel) alongside existing ones (clopidogrel, aspirin) were evaluated.
Percutaneous coronary interventions explored thrombectomy, multivessel/left main disease, and biodegradable polymers.
Medical therapies including ivabradine and rosuvastatin were assessed.
Heart failure management strategies involving beta-blockers, atrial fibrillation, and resynchronization therapy were updated.

Conclusions:

The 2009 trial data significantly advanced the understanding and treatment of cardiovascular diseases.
Clinicians must integrate these new findings into patient care for optimal outcomes.
Ongoing research continues to refine cardiovascular disease management.